ro13-9904 and Urinary-Bladder-Neoplasms

In this prospective, randomized study, the efficacy of one dose ceftriaxone or 48 hour cephradine therapy was compared to a control group to prevent urinary infection in 179 patients undergoing TUS. Only patients with low risk of developing infections were included. Both cephalosporins significantly reduced the incidence of UTI (ceftriaxone 11.9%, cephradine 17.6% compared to controls 47.2%; p less than 0.0005). Ceftriaxone seemed to have the definite edge in antibacterial spectrum and was easier to administer. Both regimens were well tolerated. Culture of prostatic chips did not have any significant predictive value to determine which patients would develop UTI.

Topics: Aged; Bacteriuria; Catheters, Indwelling; Ceftriaxone; Cephradine; Female; Humans; Male; Postoperative Complications; Premedication; Prospective Studies; Prostate; Urethra; Urinary Bladder Neoplasms; Urinary Catheterization; Urinary Tract Infections

Intravesical bacillus Calmette-Guerin (BCG) therapy, recommended for superficial bladder tumors, triggers side effects in fewer than 5% of patients. The most severe side effects, however, are septic shock and acute respiratory failure.. A 70-year-old man was hospitalized for septic shock with acute respiratory and renal failure after intravesical instillation of BCG, which was identified in the gastric aspiration sample. Treatment with rifampicin, ethambutol, isoniazid, and corticosteroid therapy, as well as standard reanimation measures, led to the patient's recovery.. This case shows the potentially severe side effects of intravesical BCG instillation. Although this treatment is well tolerated in more than 95% of patients and its systemic complications can be effectively treated, these side effects can be life-threatening.

Topics: Acute Disease; Administration, Intravesical; Aged; Anti-Bacterial Agents; BCG Vaccine; Ceftriaxone; Humans; Male; Mycobacterium bovis; Ofloxacin; Respiratory Insufficiency; Shock, Septic; Urinary Bladder Neoplasms